The chordoma treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 6.60% in the above-mentioned research forecast period.
Chordoma is a rare type of malignant bone cancer which occurs in most of the bones, in spine or the skull. It forms where, the skull sits on the spine, or below the spine. The chordoma initiates from a mass of cells, formed from the developing embryo. Chordoma occurs between the ages of 40-60 in adults. The diagnostic procedure for detection of chordoma is the removal and testing of sample for biopsy and MT or CT scan. The treatment criteria for chordoma treatment is the implementation of radiation therapy which used high-energy beams; such as X-ray and photons to eliminate cancer cells. Other forms of therapeutic treatments are targeted therapy, radiosurgery. The survival rate of chordoma is 10 years after diagnosis.
The increased incidence of chordoma cases and bone cancer cases, rise in geriatric population, rising initiatives by government, investment by RD in pharmaceutical companies, demand for minimally invasive surgery for chordoma treatment are predicted to drive the market growth. However, the lack of health remuneration policies, rise in cost, side effects associated with the use of chemotherapy and radiation therapy are expected to hinder the market growth. The rise of emerging markets in developing countries, rise of untapped opportunities, upcoming healthcare clinics, upcoming novel therapies are the opportunities which are projected to bolster the market growth. The lack of expertise, rise in product recalls, use of alternatives, hindrance faced in handling of sophisticated diagnostic machines are the challenges which can tamper the market growth.
Request a Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chordoma-treatment-market
On geographical estimation, North America is expected to hold the largest market share due to the rising number of bone cancer and chordoma cases. For instance, 40% of bone cancers are chondrosarcomas. Europe is also expected to show significant growth in the market due to upcoming novel pharmaceutical and research industries. Asia Pacific is also expected to account for the second largest market share due to the rise in point of care diagnostics, untapped opportunities in emerging markets, favorable healthcare remuneration policies. The Middle East and African region is also predicted to grow at a steady pace due to rise in R D activities in the healthcare domain.
The major players covered in the chordoma treatment market are AstraZeneca plc, Amgen, Inc., Actavis plc, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd , GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, Debiopharm , Bayer AG, Johnson Johnson Services, Inc , Merck Co., Inc., Optivus Proton Therapy, Inc, ProCure Treatment Centers, Inc., Varian Medical Systems, Inc. Amura Holdings Ltd., Catena pharmaceuticals Inc., Celldex Therapeutics , Eckert Ziegler BEBIG, Infinity Pharmaceuticals, Inc, Medivir, Verdict Media Limited among other domestic and global players.
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
